NVO

Novo Nordisk A/S is a Danish multinational pharmaceutical company and global leader in diabetes care and obesity treatment. The company produces insulin and GLP-1 receptor agonists including blockbuster drugs Ozempic and Wegovy for type 2 diabetes and weight management. Novo Nordisk also develops treatments for hemophilia, growth disorders, and hormone replacement therapy, with a strong pipeline in cardiometabolic diseases.